Citazione:Messaggio inserito da Marlin
Ah, i brevetti dei curcuminoidi di sintesi dell'Androscience. Sono di due anni fa, chissà se prima o poi usciranno i prodotti.
SI Marlin, queste patent online contengono al loro interno preziosi richiami teorici agli studi presenti in letteratura. non ero a conoscenza della sinergia fra SB e ASCJ 9-15, né dell'effetto antiandrogenico del DHA
-Examples of compounds capable of reducing or inhibiting, at least in part, nuclear transfer of a steroid receptor may act on the steroid-receptor complex when located in the cytoplasm of a cell.
-Compounds may target or induce conformational changes in the steroid receptor, may prevent dimerization of the steroid receptor, may interfere with the binding of cofactors to the steroid receptor and the like. Specific examples of compounds encompassed by the present invention include but are not limited to silibinin (SB) or functional derivatives thereof. 1)Silibinin has be previously demonstrated to prevent nuclear transfer of the androgen receptor. Zhu et. al., 2) Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP, Carcinogenesis 22: 1399-1403, 2001. Example 5 and FIG. 6 demonstrate Silibinin (SB) and ASCJ-15, a curcumin derirvative, are capable of acting in an additive fashion in the suppression of androgen-induced gene activation. Silibinin (SB) and ASCJ-15 were also shown to suppress prostate cancer cell growth in an additive fashion indicating SB and ASCJ-15 may have significant therapeutic utility in the treatment of steroid associated medical conditions.
When inhibiting or reducing androgen-dependent gene activation, preferably the composition includes at least one compound capable of inducing degradation of the androgen receptor and more preferably the compound is a curcumin derivative, such as ASCJ-9, ASCJ-15 and the like. Nonlimiting examples of compounds capable of inhibiting the conversion of testosterone to dihydrotestosterone (DHT) include 5-alpha-reductase inhibitors such as dutasteride, finasteride and functional derivatives and analogues and the like.
-Non-limiting examples of compounds capable of inhibiting binding between and androgen and the androgen receptor include but are not limited to bicalutamide, hyroxyflutamide and functional derivatives and analogues and the like.
-Non-limiting examples of compounds capable of inhibiting binding between an androgen receptor and the androgen response element (ARE) include docosahexaenoic acid (DHA) and functional derivatives and analogues and the like.
-Non-limiting examples of compounds capable of inhibiting nuclear transfer of an androgen receptor include silibinin (SB) and functional derivatives and analogues and the like.
Non-liming examples of compounds capable of inhibiting transcription of the androgen receptor include vitamin E succinate (VES), quercetin (QU) and functional derivatives and analogues and the like.